The Use of Psychotropic Medications in Dermatology

Psychocutaneous Medicine

Volumn , Issue , 2003, Pages 427-451

  Lee, Chai Sue ^a   Koo, John Y M ^b  

^a HENRY FORD HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 42649141778     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9780203911877-31     Document Type: Chapter

References (48)

1. Rocca P, Fonzo V, Scotta M, Zanalda E, Ravizza L. Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatr Scand 1997; 95:444-450.
2. Aguiar LM, Haskins T, Rudolph RL, et al. Double-blind placebo-controlled study of once-daily venlafaxine extended release in outpatients with GAD. In New Research Program and Abstracts of the Annual Meeting of the American Psychiatric Association; June 3, 1998; Toronto, Canada. NR643:241.
3. Entsuah R, Derivan AT, Haskins T, et al. Double-blind placebo-controlled study of once daily venlafaxine extended release and buspirone. In: New Research Program and Abstracts of the Annual Meeting of the American Psychiatric Association; June 3, 1998; Toronto, Canada, NR644:241.
4. Montgomery SA. Venlafaxine: a new dimension in antidepressant pharmacotherapy. J Clin Psychiatry 1993; 54:119-126.
5. Richelson E. Biological basis of depression and therapeutic relevance. J Clin Psychiatry 1991; 52(suppl):4-10.
6. Davidson J. Seizures and bupropion: a review. J Clin Psychiatry 1989; 50:256-261.
7. Friedel RO, Raskind MA. Relationship of blood levels of Sinequan to clinical effects in the treatment of depression in aged patients. In: Mendels J, ed. A Monograph of Recent Clinical Studies. Lawrenceville, NJ: Excerpta Medica, 1975.
8. Munro A. Monosymptomatic hypochondriacal psychosis. Br J Psychiatry 1988; 153(suppl):37-40.
9. Munro A, Chmars J. Monosymptomatic hypochondriacal psychosis: a diagnostic checklist based on 50 cases of the disorder. Can J Psychol 1982; 27:374-376.
10. Bishop ER Monosymptomatic hypochondriacal syndromes in dermatology. J Am Acad Dermatol 1983; 9:152-158.
11. Damiani JT, Flowers FP, Pierce DK. Pimozide in delusions of parasitosis. J Am Acad Dermatol 1990; 22(pt 1):312-313.
12. Hamann K, Avnstorp L. Delusions of infestation treated by pimozide: a double-blind crossover clinical study. Acta Derm Venereol (Stockh) 1982; 62:55-58.
13. Holmes VF. Treatment of monosymptomatic hypochondriacal psychosis with pimozide in an AIDS patient (lett). Am J Psychiatry 1989; 146(4):554-555.
14. Lindskov R. Delusions of infestations treated with pimozide. Acta Derm Venereol 1985; 65:267-270.
15. Driscoll MS, Rothe MJ, Grant-Kels JM, et al. Delusional parasitosis: a dermatologic, psychiatric and pharmacologic approach. JAAD 1993; 29:1023-1033.
16. Schatzberg AF, Cole JO, DeBattista C. Manual of Clinical Psychopharmacology. 3rd ed. Washington, DC: APA Press 1997, 154-155.
17. Stahl SM. Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials. J Clin Psychiatry 1999; 60(suppl 10):31-41.
18. Brown CS, Markowitz JS, Moore TR, Parker NG. Atypical antipsychotics: part II adverse effects, drug interactions and costs. Ann Pharmacother 1999; 33:210-217.
19. Meltzer HY. New drugs for the treatment of schizophrenia. Psychiatr Clin North Am 1993; 16:365-385.
20. Deutch AY, Moghaddam B, Innis RB, et al. Mechanisms of action of atypical antipsychotic drugs: implications for novel therapeutic strategies for schizophrenia. Schizophr Res 1991, 4:121-156.
21. Gerlach J. New antipsychotics: classifications, efficacy and adverse effects. Schizophr Bull 1991; 17:289-309.
22. Davis KL, Kahn RS, Ko G, et al. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 1991; 148:1474-1486.
23. Physicians’ Desk Reference. Montvale, NJ: Medical Economics, 1998.
24. Schotte A, Janssen PFM, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 1996; 124:57-73.
25. Borison RL. Clinical efficacy of serotonin-dopamine antagonists relative to classic neuroleptics. J Clin Psychopharmacol 1995; 15:24S–29S.
26. Casey DE. Side effect profiles of new antipsychotic agents. J Clin Psychiatry 1996; 57(suppl 11):40S–45S.
27. Prescribing information. Risperdal (risperidone). Titusville, NJ: Janssen Pharmaceuticals, 1996.
28. Hansen TE, Casey DE, Hoffman WF. Neuroleptic intolerance. Schizophr Bull 1997; 23:567-582.
29. Arvanitis LA, Miller BG. ICI 204, 636, an atypical antipsychotic: results from a multiple fixed-dose, placebo-controlled trial (abstr). Psychopharmacol Bull 1996; 32(3):391.
30. Hong WW, Arvanitis LA, Miller BG, et al. The atypical profile of ICI 204, 636 is supported by its lack of induction of extrapyramidal symptoms (abstr). Psychopharmacol Bull 1996; 32(3):458.
31. Arvanitis LA, Miller BG, and the Seroquel Trial 13 Study Group. Multiple fixed doses of ‘‘Seroquel’’ (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997; 42:233-246.
32. Prescribing information. Seroquel (quetiapine). Wilmington, DE: Zeneca Pharmaceuticals, 1998.
33. Leonard HL. New developments in the treatment of obsessive-compulsive disorder. J Clin Psychiatry 1997; 58(suppl 14):39-45.
34. Rasmussen SA, Eisen JL. Treatment strategies for chronic and refractory obsessive-compulsive disorder. J Clin Psychiatry 1997; 58(suppl 13):9-13.
35. Watson CP, Evans RJ, Reed K, et al. Amitriptyline versus placebo in postherpetic neuralgia. Neurology 1982; 32:671-673.
36. Max MB, Schafer SC, Culnane M, et al. Amitriptyline, but not lorazepam, relieves postherpetic neuralgia. Neurology 1988; 38:1427-1432.
37. Watson CPN, Chipman M, Reed K, et al. Amitriptyline versus maprotiline in postherpetic neuralgia: a randomized, double-blind crossover trial. Pain 1992; 48:29-36.
38. Feinmann C, Harris M, Cawley R. Psychogenic facial pain: presentation and treatment. Br Med J 1984; 288:436-438.
39. Urban BJ, France FD, Maltbie AA, et al. Long-term use of narcotic/ antidepressant medication in the management of phantom limb pain. Pain 1986; 24:191-196.
40. Eberhard G, von Knorring L, Nilsson HL, et al. A double-blind randomized study of clomipramine versus maprotiline in patients with idiopathic pain syndromes. Neuropsychobiology 1988; 19:25-34.
41. Bernstein JE, Whitney DH, Soltani K. Inhibition of histamine-induced pruritus by topical tricyclic antidepressants. J Am Acad Dermatol 1981; 5:582-585.
42. Savin JA, Paterson WD, Adam K, et al. Effects of trimeprazine and trimipramine on nocturnal scratching in patients with atopic eczema. Arch Dermatol 1979; 115:313-315.
43. Figueiredo A, Ribeiro CA, Goncalo M, et al. Mechanism of action of doxepin in the treatment of chronic urticaria. Fundam Clin Pharmacol 1990; 4(2):147-158.
44. Lawlor F, Greaves MW. The development of recent strategies in the treatment of urticaria as a result of clinically oriented research. Zeitschr Hautkrankh 1990; 65(1):17-27.
45. Kishore-Kumar R, Max MB, Schafer SC, et al. Desipramine relieves postherpetic neuralgia. Clin Pharmacol Ther 1990; 47:305-312.
46. Boyer WI. Potential indications for the selective serotonin reuptake inhibitors. Int J Clin Psychopharmacol 1992; 6(suppl 5):5-12.
47. Bernstein JE, Whitney DH, Soltani K. Inhibition of histamine-induced pruritus by topical tricyclic antidepressants. J Am Acad Dermatol 1981; 5:582-585.
48. Wolverton SE. Comprehensive Dermatologic Drug Therapy. Philadelphia: WB Saunders 2001:402-425.